Glioma refers to a type of tumor that starts in the glial cells of the brain and spine. The prognosis of patients with glioma is poor, and new treatments are promptly needed. This study aims to compare the overall survival of patients with high-grade glioma receiving tumor resection, followed by vocimagene amiretrorepvec with flucytosine or standard care alone.
This randomized, open-label phase 2/3 trial included a total of 403 patients with high-grade glioma receiving who had received tumor resection for first or second recurrence of the disease. The patients were randomly assigned in a 1:1 ratio to receive vocimagene amiretrorepvec-flucytosine or standard care. The primary outcome of the study was the overall survival from randomization to death.
The final analysis of the trial included 271 deaths during a median follow-up of 22.8 months. The median overall survival was 11.10 months in the vocimagene amiretrorepvec-flucytosine group and 12.22 months in the control group. The secondary outcomes, including safety, durable response rate, durable clinical benefit rate, and 12-month overall survival, didn’t differ drastically.
The research concluded that treatment with amiretrorepvec-flucytosine was not superior to standard care among patients who underwent tumor resection for high-grade glioma.